login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Revolutionary impact of flow diversion/modification on treatment of certain aneuryms


Friday, 30 Sep 2011 11:45
Saruhan Çekirge
Saruhan Çekirge


Saruhan Çekirge, professor, Hacettepe University Hospitals, Ankara,Turkey, told delegates at the European Society of Minimally Invasive Neurological Therapy congress (ESMINT) held in Nice, France, that the impact of flow diversion/modification on the endovascular treatment of aneurysms with an important branch originating from the aneurysm sac was a “revolutionary change”.


He also told delegates: “In endovascular aneurysm treatment with flow diverters, there has been a strong consideration regarding the side branch or perforator patency. There have been anecdotal cases reporting perforating injury in the literature. In our experience, covering a segment, with branches coming off, with flow diverters especially with a single device, does not result in clinical consequence. If there is a flow demand, the vessel stays open; if not, it may close or become hypoplastic. This is most interesting that if there is a flow demand it stays open, so there is very intelligent behaviour.”


“Control studies have shown that flow diversion/modification treatment provides revolutionary changes not only for aneurysms which are large/giant and fusiform, for very small, difficult or impossible- to-coil ones and also for aneurysms with an important vessel coming off the sac which used to be the major limitation for endovascular treatment,” he added.


In the Hacettepe FD Pipeline/Silk series of 269 aneurysms in 211 patients, there was a subgroup of 46 aneurysms with a vessel originating from the aneurysm sac. In this group of 46 aneurysms with a vessel originating from the aneurysm sac, 23 aneurysms were in the internal carotid-anterior choroidal artery, 11 in the posterior communicating, four in the posterior inferior coronary artery, two in the distal anterior cerebral artery, one in the distal posterior communicating artery and five in the middle cerebral artery with important side branches originating .

 

“In 33 of these 46 aneurysms, six months and/or one year follow-up DSA was obtained. Investigators found that out of these 33 aneurysms which were controlled, all but one vessel (posterior communicating artery) originating from the aneurysm sac stayed open. Twenty aneurysms closed with perfect reconstruction and 13 aneurysm sacs were remodeled back. No clinical consequences developed except for one patient with an internal carotid-anterior choroidal aneurysm who stopped using clopidogrel after one week and had a transient ischaemic attack with a very small diffusion MR lesion in the territory. This patient returned to normal in 24 hours and a six-month control DSA revealed complete aneurysm occlusion with patency of the artery,” said Çekirge.




Add New Comment

Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions